US4769336A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of factor VIII inhibitors
Assignee: Scripps Research Institute
•
Filing: 1987-02-12
•
Granted: 1988-09-06
•
Expires: 2007-02-12
Abstract
Abstract Fragments of human Factor VIII:C which bind to antibody inhibitors of Factor VIII in patients afflicted with such inhibitors are disclosed. The method of treating Factor VIII inhibitors, by administering one or more of these fragments, is also disclosed.
Inventors
- 👤 Theodore S. Zimmerman
- 👤 Carol A. Fulcher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:01
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/86; C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; G01N2333/00; G01N2333/435; G01N2333/745; G01N2333/755; Y; Y10; Y10S; Y10S436/00; Y10S436/815; Y10S436/824; Y10S930/00; Y10S930/01; Y10S930/10
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
201 words
A method for detecting the presence of an antibody inhibitor of human Factor VIII in a sample, comprising (a) immobilizing on a solid substrate a polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII; (b) contacting the immobilized polypeptide with the sample; and then (c) analyzing the immobilized polypeptide to determined whether it has bound an antibody inhibitor; wherein said fragment of human Factor VIII is selected from the group consisting of: (i) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 394-465; (ii) fragments whose amino-terminal residue is one of residues 395-466 and whose carboxyl-terminal residue is one of residues 472-492; (iii) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 472-492; (iv) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1708-1775; (v) fragments whose amino-terminal residue is one of residues 1709-1776 and whose carboxyl-terminal residue is one of residues 1782-1802; and (vi) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1782-1802.
Claim 2
Independent Claim
201 words
A method for detecting the presence of an antibody inhibitor of human Factor VIII in a sample, comprising (a) immobilizing on a solid substrate a polypeptide which neutralizes the activity of Factor VIII inhibitor and whose amino acid sequence is that of a fragment of human Factor VIII; (b) contacting the immobilized polypeptide with the sample; and then (c) analyzing the immobilized polypeptide to determined whether it has bound an antibody inhibitor; wherein said fragment of human Factor VIII is selected from the group consisting of: (i) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 394-465; (ii) fragments whose amino-terminal residue is one of residues 395-466 and whose carboxyl-terminal residue is one of residues 472-492; (iii) fragments whose amino-terminal residue is one of residues 360-380 and whose carboxyl-terminal residue is one of residues 472-492; (iv) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1708-1775; (v) fragments whose amino-terminal residue is one of residues 1709-1776 and whose carboxyl-terminal residue is one of residues 1782-1802; and (vi) fragments whose amino-terminal residue is one of residues 1674-1694 and whose carboxyl-terminal residue is one of residues 1782-1802.
Claim 3
Dependent Claim
53 words
The method of claim 1 wherein step (c) comprises (1) reacting the immobilized polypeptide with a monoclonal antibody to human IgG; then (2) reacting the antibody used in step (1) with a radiolabeled antibody thereto; and (3) analyzing the immobilized polypeptide to detect the presence or absence of radioactivity from said radiolabeled antibody.
References Cited (Backward Citations)
US4578218A
Cited
US4716117A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-06 | 1992-03-07 | 1992-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-06 | 1996-03-07 | 1996-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-06 | 2000-03-07 | 2000-09-06 | $7700.00 | Window Closed / Lapsed |